¥9.50   ( %)
前日收盘: 当日成交量(股): 当日最高: 总股本:3176.92万
当日开盘: 当日成交额(元): 当日最低: 流通股本:
市盈率(动/静):0/0 市净率:0 市销率:0 总市值:3.02亿
52周最高:16.75 52周最低:6.51 转让方式: 单位:美元
$Evelo Biosciences(EVLO)$
  • 还可以输入
  • 20016

Evelo Biosciences(EVLO) 02月15日 03时11分

新闻 Evelo Biosciences Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights -- First Patient Dosed in University of Chicago Phase 2a Trial of EDP1503 in Metastati ......  url.vc.watch/rBrG
查看全文

Evelo Biosciences(EVLO) 02月10日 01时24分

新闻 Evelo Biosciences to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 14, 2019 CAMBRIDGE, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. ( ......  url.vc.watch/rA1X
查看全文

Evelo Biosciences(EVLO) 01月29日 01时05分

新闻 Evelo Biosciences Announces Dosing of First Patient in Investigator-Sponsored Phase 2a Clinical Trial of EDP1503 in Combination with KEYTRUDA® in Patients with Metastatic Melanoma - I ......  url.vc.watch/r7t5
查看全文

Evelo Biosciences(EVLO) 01月18日 04时41分

公告 Evelo Biosciences, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Bodmer Mark
公告日:2019-01-16, 内部交易人:Bodmer Mark, 与发行人关系:CSO, President of R&D/高管/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2019-01-14, SEC Accession No. 0001694665-19-000006, File:https://www.sec.gov/Archives/edgar/data/1694665/000169466519000006/0001694665-19-000006-index.htm $Evelo Biosciences(EVLO)$
查看全文

Evelo Biosciences(EVLO) 01月18日 04时41分

公告 Evelo Biosciences, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:GILL SIMBA
公告日:2019-01-16, 内部交易人:GILL SIMBA, 与发行人关系:President & CEO/董事/高管/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2019-01-14, SEC Accession No. 0001694665-19-000004, File:https://www.sec.gov/Archives/edgar/data/1694665/000169466519000004/0001694665-19-000004-index.htm $Evelo Biosciences(EVLO)$
查看全文

Evelo Biosciences(EVLO) 01月18日 04时41分

公告 Evelo Biosciences, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Poole Jonathan
公告日:2019-01-16, 内部交易人:Poole Jonathan, 与发行人关系:CFO/高管/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2019-01-14, SEC Accession No. 0001694665-19-000002, File:https://www.sec.gov/Archives/edgar/data/1694665/000169466519000002/0001694665-19-000002-index.htm $Evelo Biosciences(EVLO)$
查看全文

Evelo Biosciences(EVLO) 01月11日 15时29分

查看全文

Evelo Biosciences(EVLO) 01月04日 23时18分

新闻 Evelo Biosciences Announces Dosing of First Patient in Phase 1/2 Clinical Trial of EDP1503 in Combination with KEYTRUDA® (pembrolizumab) in Multiple Oncology Indications -- Initial Clin ......  url.vc.watch/n0iW
查看全文

Evelo Biosciences(EVLO) 2018年12月11日 02时35分

查看全文

Evelo Biosciences(EVLO) 2018年12月05日 22时33分

新闻 Evelo Biosciences to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference CAMBRIDGE, Mass., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq ......  url.vc.watch/nfvu
查看全文

Evelo Biosciences(EVLO) 2018年11月29日 02时05分

新闻 Evelo Biosciences Announces First Dosing in Phase 1b Clinical Trial of EDP1815 in Psoriasis and Atopic Dermatitis Data Expected in Second Half of 2019 CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE ......  url.vc.watch/nUmL
查看全文

Evelo Biosciences(EVLO) 2018年11月29日 02时05分

新闻 Evelo Enters into Clinical Trial Collaboration Agreement with Merck
-- Initiation of Phase 1/2 Combination Clinical Trial with Evelo's Monoclonal Microbial, EDP1503, and KEYTRUDA® (pembroliz ......  url.vc.watch/nUmq
查看全文

Evelo Biosciences(EVLO) 2018年11月13日 22时46分

新闻 Report: Developing Opportunities within Evelo Biosciences, ADMA Biologics, Karyopharm Therapeutics, Pingtan Marine Enterprise, Rosetta Stone, and Williams Companies — Fut ......  url.vc.watch/nxn9
查看全文

Evelo Biosciences(EVLO) 2018年11月07日 22时34分

新闻 Evelo Biosciences to Present at Upcoming Investor Conferences in November
CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) ("Evelo"), a c ......  url.vc.watch/nOWY
查看全文

Evelo Biosciences(EVLO) 2018年11月03日 02时18分

查看全文

Evelo Biosciences(EVLO) 2018年11月02日 11时12分

公告 Evelo Biosciences, Inc. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Char Daniel
公告日:2018-11-01, 内部交易人:Char Daniel, 与发行人关系:General Counsel/高管/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-10-31, SEC Accession No. 0001694665-18-000008, File:https://www.sec.gov/Archives/edgar/data/1694665/000169466518000008/0001694665-18-000008-index.htm $Evelo Biosciences(EVLO)$
查看全文

Evelo Biosciences(EVLO) 2018年11月02日 11时11分

查看全文

Evelo Biosciences(EVLO) 2018年11月02日 02时15分

Evelo Biosciences(EVLO) 2018年11月01日 23时05分

新闻 Evelo Biosciences Reports Third Quarter 2018 Financial Results and Recent Business Highlights
-- Approval to Initiate Phase 1b Trial of EDP1815 in Psoriasis and Atopic Dermatitis: Dosing o ......  url.vc.watch/JYoY
查看全文

Evelo Biosciences(EVLO) 2018年09月07日 01时38分

新闻 Evelo Biosciences to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) (&quo ......  url.vc.watch/jo5Q
查看全文
  • 首页 上一页 1 2 3 下一页 尾页  每页20条/共78